BON stock forecast, quote, news & analysis
Bon Natural Life Ltd focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by its customers... Show more
Why Bon Natural Life Limited (BON) Is Down -12% in the Last 30 Days
Key Takeaways
- BON stock declined approximately -12% over the past 30 days, reflecting ongoing volatility in the specialty chemicals sector and limited market reaction to recent partnerships.
- Over the past quarter, the stock fell around -23%, amid broader downward pressure from weak revenue growth reported in interim results and thin trading volumes.
- Key drivers include revenue declines in recent financials, despite operational income improvements, and a lack of significant analyst coverage or upgrades.
- Recent announcements like partnerships with Tigerbone Group and product developments have not sufficiently countered negative sentiment in natural ingredients market.
- Macro factors such as fluctuating demand for functional foods and personal care ingredients contributed to range-bound, downward-trending price movement.
Bon Natural Life Limited (BON) Company Overview and Market Position
Bon Natural Life Limited (BON) is a biotech company focused on the research, development, manufacture, and sale of functional active ingredients extracted from natural herb plants. Headquartered in Xi'an, China, the company serves markets in China, Europe, North America, and the Middle East with products including plant-extracted fragrance compounds for perfumes and natural health supplements like powder drinks and bioactive food additives. These are used in functional foods, personal care, cosmetics, and pharmaceuticals.
BON's core business model relies on bio-manufacturing and direct distribution to manufacturers, positioning it in the competitive specialty chemicals and nutraceuticals industry. Its exposure to natural and sustainable ingredients aligns with growing consumer demand for clean-label products, but recent stock behavior reflects challenges like revenue pressures and market skepticism toward small-cap Chinese firms, contributing to downward price movement despite innovation efforts.
Bon Natural Life Limited (BON) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BON stock has been down approximately -12%, moving from around $1.49 to $1.31. The price action has been volatile and range-bound, with lows near $1.13 in late March and partial recoveries, but overall trend-driven lower amid low daily volumes averaging under 50,000 shares.
For the past quarter, the stock declined about -23%, from roughly $1.71 to $1.31. Performance featured a steady downtrend with intermittent fluctuations, hitting intra-period highs near $1.74 early on before sliding, characteristic of thinly traded micro-cap stocks sensitive to news flow.
What Drove BON Stock Price in the Last 30 Days
The 30-day decline in BON's stock price stems primarily from continued digestion of weaker revenue figures from the six months ended March 31, 2025, which showed a 21.9% drop to $7.95 million despite operational income rising 236% to $284,050. This mixed financial picture failed to inspire confidence amid thin liquidity.
Company-specific news, including a strategic partnership with Tigerbone Group for natural health initiatives and announcements on an Apple bio-electronic mask targeting medical aesthetics, elicited limited positive response, as investors questioned execution in competitive markets. No major analyst upgrades or earnings releases occurred, while sector sentiment in specialty chemicals remained cautious due to softening demand for personal care ingredients. Macro influences like global supply chain pressures on herb extracts exacerbated the downward pressure, leading to the observed price movement.
What Drove BON Stock Performance Over the Last Quarter
The quarterly downturn was propelled by sustained revenue challenges highlighted in interim 2025 results, with total revenues down significantly year-over-year, overshadowing cost efficiencies and operational gains. This reflected broader industry headwinds in natural products, including fluctuating raw material costs and weaker demand in functional foods and cosmetics.
Larger narratives included a $12 million sales agreement with Qingshengyuan for kombucha-inspired products and AI-driven biomanufacturing lab partnerships, but these failed to reverse the trend amid macroeconomic conditions like inflation impacting consumer spending on supplements. Competitive positioning in China's bio-extracts market faced scrutiny, with institutional interest low and high short interest potential amplifying declines. Cumulative impact from low visibility and micro-cap volatility dominated, resulting in the -23% drop.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, which analyze and trade thousands of tickers across various markets. These bots employ diverse strategies such as trend-following, mean reversion, or momentum plays, spanning short-term day trades to long-term positions, with performance metrics like win rate, profit factor, and Sharpe ratio highlighted for transparency. Curated based on recent success and relevance to current market trends, the section helps users identify bots suited to their risk tolerance and goals. Explore Trending AI Robots to discover automated tools that could enhance your stock analysis and trading decisions.
BON Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming earnings reports, particularly the full-year 2025 20-F filing, for updates on revenue recovery and profitability margins. Industry trends in natural ingredients and bio-manufacturing, including demand for sustainable supplements, remain key.
The macro environment, encompassing China economic data, global inflation, and supply chain stability for herb extracts, could sway sentiment. Strategic developments like progress on partnerships (e.g., Tigerbone, Qingshengyuan) and new product launches in health and aesthetics warrant attention. Risks include forex fluctuations for a China-based firm, regulatory changes in pharma/cosmetics, and competition from larger players, alongside potential catalysts from Nasdaq compliance or expanded distribution deals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
BON sees its Stochastic Oscillator climbs out of oversold territory
On April 01, 2026, the Stochastic Oscillator for BON moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BON's RSI Oscillator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on April 15, 2026. You may want to consider a long position or call options on BON as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BON just turned positive on April 08, 2026. Looking at past instances where BON's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
BON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BON entered a downward trend on April 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.184) is normal, around the industry mean (4.882). P/E Ratio (0.079) is within average values for comparable stocks, (82.508). BON's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.023). BON has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.192) is also within normal values, averaging (141.665).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ChemicalsSpecialty